Victory Capital Management’s Ovid Therapeutics OVID Stock Holding History

Victory Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$51.3K	Buy	20,596 +1,248	+6%	+$3.27K	﹤0.01%	2435
2026 Q2	$52K	Buy	19,348 +6,182	+47%	+$16K	﹤0.01%	2393
2026 Q1	$29.2K	Buy	+13,166	New	+$23.5K	﹤0.01%	2357
2020 Q2	–	Sell	-5,937	Closed	-$18K	–	3041
2020 Q1	$18K	Buy	+5,937	New	+$20K	﹤0.01%	2877
2019 Q4	–	Sell	-4,694	Closed	-$15K	–	3072
2019 Q3	$15K	Buy	+4,694	New	+$10.7K	﹤0.01%	3136
2018 Q1	–	Sell	-105,470	Closed	-$1.04M	–	1895
2017 Q4	$1.04M	Buy	105,470 +4,440	+4%	+$40.8K	﹤0.01%	1219
2017 Q3	$866K	Sell	101,030 -29,970	-23%	-$250K	﹤0.01%	1241
2017 Q2	$1.37M	Buy	+131,000	New	+$1.71M	﹤0.01%	1088

Other funds holding OVID

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Victory Capital Management's OVID Position: Q3 2026 in Review

Victory Capital Management increased its Ovid Therapeutics (OVID) stake by 6.5% in Q3 2026, buying an estimated $3.27K and bringing the position to 20,596 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Victory Capital Management first reported a position in OVID in Q2 2017 and has held it in 8 quarters since. The position peaked at $1.37M in Q2 2017. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

Victory Capital Management held 20,596 shares of Ovid Therapeutics worth $51.3K as of Q3 2026.
Victory Capital Management bought 1,248 Ovid Therapeutics shares in Q3 2026, an estimated $3.27K.
Ovid Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #2435 holding.
Victory Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 8 quarters since.
Victory Capital Management's Ovid Therapeutics position peaked at $1.37M in Q2 2017.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.